8IG8
Crystal structure of SARS-Cov-2 main protease S46F mutant in complex with GC376
8IG8 の概要
エントリーDOI | 10.2210/pdb8ig8/pdb |
分子名称 | 3C-like proteinase nsp5, N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide (3 entities in total) |
機能のキーワード | viral protein-inhibitor complex, viral protein/inhibitor |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 67857.50 |
構造登録者 | |
主引用文献 | Lin, C.,Zhu, Z.,Jiang, H.,Zou, X.,Zeng, X.,Wang, J.,Zeng, P.,Li, W.,Zhou, X.,Zhang, J.,Wang, Q.,Li, J. Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376. J.Mol.Biol., 436:168474-168474, 2024 Cited by PubMed Abstract: The main protease (M) of coronaviruses participates in viral replication, serving as a hot target for drug design. GC376 is able to effectively inhibit the activity of M, which is due to nucleophilic addition of GC376 by binding covalently with Cys145 in M active site. Here, we used fluorescence resonance energy transfer (FRET) assay to analyze the IC values of GC376 against Ms from six different coronaviruses (SARS-CoV-2, HCoV-229E, HCoV-HUK1, MERS-CoV, SARS-CoV, HCoV-NL63) and five M mutants (G15S, M49I, K90R, P132H, S46F) from SARS-CoV-2 variants. The results showed that GC376 displays effective inhibition to various coronaviral Ms and SARS-CoV-2 M mutants. In addition, the crystal structures of SARS-CoV-2 M (wide type)-GC376, SARS-CoV M-GC376, MERS-CoV M-GC376, and SARS-CoV-2 M mutants (G15S, M49I, S46F, K90R, and P132H)-GC376 complexes were solved. We found that GC376 is able to fit into the active site of Ms from different coronaviruses and different SARS-CoV-2 variants properly. Detailed structural analysis revealed key molecular determinants necessary for inhibition and illustrated the binding patterns of GC376 to these different Ms. In conclusion, we not only proved the inhibitory activity of GC376 against different Ms including SARS-CoV-2 M mutants, but also revealed the molecular mechanism of inhibition by GC376, which will provide scientific guidance for the development of broad-spectrum drugs against SARS-CoV-2 as well as other coronaviruses. PubMed: 38311236DOI: 10.1016/j.jmb.2024.168474 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.73 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード